Skip to content

Neuronetics STIM Restricted Cash

Restricted Cash at other companies

LBR
LB Pharmaceuticals Inc Common StockLBRX
$776K
Stereotaxis logo
StereotaxisSTXS
$6.97M+1,348%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$852K+598%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$923K
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$592K-76.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-59.6%
Enterprise value$162.64M-44.6%
P/S0.6×-1.4×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's restricted cash?
Neuronetics (STIM) reported restricted cash of $5.75M in Q1 2026.
How has Neuronetics's restricted cash changed year-over-year?
Neuronetics's restricted cash increased by 475.0% year-over-year, from $1M to $5.75M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.